COMMENT
EDITORIAL
Add like
Add dislike
Add to saved papers

Paradigm shift in the management of metabolic diseases - next generation incretin therapy.

Endocrinology 2023 November 11
Recently impressive weight loss has been reported for novel incretin therapies based on dual and triple hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases where weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases and non-alcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app